Block Listing Application

RNS Number : 1759W
ConvaTec Group PLC
20 December 2021
 

ConvaTec Group Plc

 

Block Listing Application

 

 

Reading, United Kingdom - 20 December 2021

 

 

An application has been made to the Financial Conduct Authority and the London Stock Exchange for a block listing totalling 20,000,000 ordinary shares of 10 pence each ("Shares") to be admitted to the premium listing segment of the Official List of the FCA and to trading on the London Stock Exchange's main market for listed securities. When issued these Shares will rank pari passu with the existing ordinary shares.

 

 

These Shares are being reserved under a block listing and will be issued from time to time pursuant to the following scheme(s):

 

Scheme

Number of Shares

ConvaTec Group Plc Long Term Incentive Plan

9,850,000

ConvaTec Group Plc US Employee Stock Purchase Plan

290,000

ConvaTec Group Plc Share Plan

3,000,000

ConvaTec Group Plc Deferred Bonus Plan

430,000

ConvaTec Group Plc UK SAYE

1,830,000

ConvaTec Group Plc Global SAYE Sub-Plan

4,600,000

 


Admission of the Shares is expected on 21 December 2021.

 

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations, ConvaTec   +44 (0)782 644 7807

ir@convatec.com

 

Media

Buchanan: Chris Lane        +44 (0)207 466 5000          

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit  www.convatecgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ALSFEASWSEFSELE
UK 100

Latest directors dealings